A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Lymphoma Research/Clinical Trials Bookmark and Share

Lymphoma Research and Care: New Treatments Start With Clinical Trials

City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute (NCI) and many other research-based organizations, and our scientists collaborate with other leading research institutions to develop tomorrow’s breakthroughs today.
 
With our extensive program of lymphoma clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
 
and  Christine Brown, Ph.D., associate director of the T-cell Immunotherapy Laboratory, have opened an Food and Drug Administration (FDA )- approved clinical trial of an investigational drug for patients with T-cell lymphoma who are undergoing transplantation for recurrent disease, to reduce the chance of relapse. Plans are now underway to extend this promising new therapy to treat patients with B-cell lymphoma who are not undergoing transplantation. That trial is expected to begin this year.
 
Amrita Y. Krishnan, M.D., director, Multiple Myeloma Program, is leading an international clinical trial to test whether Zevalin radioimmunotherapy given prior to high-dose chemotherapy plus autologous stem cell transplantation will reduce the rate of disease recurrence and improve overall and disease-free survival in patients with aggressive lymphoma. City of Hope was the first institution to show that hematopoietic stem cell transplantation could cure patients of lymphoma who suffered from HIV infection. This has changed the standard of care for patients in the U.S. Joseph Alvarnas, M.D., associate clinical professor of hematology and hematopoietic cell transplantation is leading a national trial in the treatment of patients with lymphoma and HIV infection. He is also leading a study aimed at determining whether allogeneic (donor) transplants will cure both leukemia and HIV infection.
 
Leslie Popplewell, M.D., associate clinical professor , and Robert Chen, M.D., assistant professor, both of the Department of Hematology & Hematopoietic Cell Transplantation, continue to advance clinical trials of new agents that may be more effective and less toxic in treating patients with hematologic cancers. Chen led a national study of the drug brentuximab in patients with relapsed Hodgkin disease, in whom the drug produced a high rate of response. The drug was subsequently approved by the FDA. Current research is directed at assessing the efficacy of brentuximab in preparing patients for transplant, as well as in preventing posttransplant relapse.
 
 

Lymphoma Research/Clinical Trials

Lymphoma Research and Care: New Treatments Start With Clinical Trials

City of Hope has long been a leader in lymphoma research. Our research projects have been funded by the National Cancer Institute (NCI) and many other research-based organizations, and our scientists collaborate with other leading research institutions to develop tomorrow’s breakthroughs today.
 
With our extensive program of lymphoma clinical trials, City of Hope can provide our patients access to novel therapies, including many that are not available elsewhere.
 
and  Christine Brown, Ph.D., associate director of the T-cell Immunotherapy Laboratory, have opened an Food and Drug Administration (FDA )- approved clinical trial of an investigational drug for patients with T-cell lymphoma who are undergoing transplantation for recurrent disease, to reduce the chance of relapse. Plans are now underway to extend this promising new therapy to treat patients with B-cell lymphoma who are not undergoing transplantation. That trial is expected to begin this year.
 
Amrita Y. Krishnan, M.D., director, Multiple Myeloma Program, is leading an international clinical trial to test whether Zevalin radioimmunotherapy given prior to high-dose chemotherapy plus autologous stem cell transplantation will reduce the rate of disease recurrence and improve overall and disease-free survival in patients with aggressive lymphoma. City of Hope was the first institution to show that hematopoietic stem cell transplantation could cure patients of lymphoma who suffered from HIV infection. This has changed the standard of care for patients in the U.S. Joseph Alvarnas, M.D., associate clinical professor of hematology and hematopoietic cell transplantation is leading a national trial in the treatment of patients with lymphoma and HIV infection. He is also leading a study aimed at determining whether allogeneic (donor) transplants will cure both leukemia and HIV infection.
 
Leslie Popplewell, M.D., associate clinical professor , and Robert Chen, M.D., assistant professor, both of the Department of Hematology & Hematopoietic Cell Transplantation, continue to advance clinical trials of new agents that may be more effective and less toxic in treating patients with hematologic cancers. Chen led a national study of the drug brentuximab in patients with relapsed Hodgkin disease, in whom the drug produced a high rate of response. The drug was subsequently approved by the FDA. Current research is directed at assessing the efficacy of brentuximab in preparing patients for transplant, as well as in preventing posttransplant relapse.
 
 
Quick Links
A $10 million gift from Internet-publishing entrepreneurs Emmet and Toni Stephenson and their daughter Tessa Stephenson Brand will fund the creation of the Toni Stephenson Lymphoma Center at City of Hope, the cornerstone of the institution’s new Hematologic Cancers Institute.
Hematologic Cancers Support Groups
Low-dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction Trial
 
A clinical research study is currently underway to see if low-dose tamoxifen can reduce the risk of breast cancer in childhood, adolescent, and young adulthood cancer survivors.
NEWS & UPDATES
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...
  • The leading risk factor for breast cancer is simply being a woman. The second top risk factor is getting older. Obviously, these two factors cannot be controlled, which is why all women should be aware of their risk and how to minimize those risks. Many risk factors can be mitigated, and simple changes can lead...
  • All women are at some risk of developing the disease in their lifetimes, but breast cancer, like other cancers, has a disproportionate effect on minorities. Although white women have the highest incidence of breast cancer, African-American women have the highest breast cancer death rates of all racial and ethni...
  • First, the good news: HIV infections have dropped dramatically over the past 30 years. Doctors, researchers and health officials have made great strides in preventing and treating the disease, turning what was once a death sentence into, for some, a chronic condition. Now, the reality check: HIV is still a worl...
  • Screening for breast cancer has dramatically increased the number of cancers found before they cause symptoms – catching the disease when it is most treatable and curable. Mammograms, however, are not infallible. It’s important to conduct self-exams, and know the signs and symptoms that should be checked by a h...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free.   In his previ...
  • In a single day, former professional triathlete Lisa Birk learned she couldn’t have children and that she had breast cancer. “Where do you go from there?” she asks. For Birk, who swims three miles, runs 10 miles and cycles every day, the answer  ultimately was a decision to take control of her cancer care. Afte...
  • More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools. Today there are nearly 14.5 million cancer survivors in the United States. But in up to 20 percent of cancer patients, the disease ultimately spreads to their brain. Each year, nearly 170,000 new cases of brain ...
  • Cancer cells are masters of survival. Despite excessive damage to their most basic workings and the constant vigilance of the body’s immune system, they manage to persevere. Much of this extraordinary ability to survive falls under the control of proteins bearing the name STAT, short for signal transducer and a...
  • One person receives the breast cancer diagnosis, but the cancer affects the entire family. Couples, in particular, can find the diagnosis and treatment challenging, especially if they have traditional male/female communication styles. “Though every individual is unique, men and women often respond differently d...
  • Here’s a statistic you’ll hear and read frequently over the next month: One in eight women born in the United States will develop breast cancer at some point in her lifetime. Although this statement is accurate, based on breast cancer incidence rates in 2013, it’s often misunderstood. Leslie Bernstein, Ph.D., d...
  • This time of year, how can anyone not think pink? Through the power of pastel packaging, October has been etched permanently into the American public’s consciousness as Breast Cancer Awareness Month. The color pink is now synonymous with breast cancer. Suffice to say, awareness has been raised. Now itR...